Obatoclax Mesylate (GX15-070)

Catalog No.S1057

Obatoclax Mesylate (GX15-070) Chemical Structure

Molecular Weight(MW): 413.49

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 320 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

9 Customer Reviews

  • In vivo antitumor efficacies of AZD2281 and GX15-070 alone or in combination in a BxPC-3 xenograft model. Tumor specimens were fixed in 10% formalin, embedded in paraffin, and cut into 4 lm-thick slides for H&E, PCNA, and CD34 staining.

    Cancer Lett 2014 348, 20-8. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    Gx15-070 induces autophagy and necroptosis in TET cells. Time-course electron microscopic morphology of T1682 cells treated with Gx15-070 at the indicated concentrations. After 1-h treatment, lamellar bodies (yellow arrow) consistent with early signs of autophagy and mitochondrial structural changes with loss of cristae (orange arrow) were evident. After 6-h treatment, early signs of necroptosis with intact nuclear envelope (top panel), and mitochondrial swelling with loss of mitochondrial matrix and cytoplasm vacuolization were observed (bottom panel). After 48-h treatment, late stages of necroptotic cell death (yellow arrow) and advanced stages of autophagy (orange arrow) were evident. The bottom panel depicts advanced stage of autophagic cell death with cytoplasmic vacuolization and lamellar bound structures consistent with autophagosomes.

    Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • ffect of Gx15-070 of mTOR pathway and on AMPKα. Effect of 6h Gx15-070 treatment on T1682 cells compared with untreated cells and cells starved for 6 h. The treatment induced a progressive reduction of p-AKT (Ser473 and Thr308) and p-RPS6 with the exception of 500 nM concentration. Progressive increase of LC3B-II and AMPKα phosphorylation was observed in Gx15-070 concentration-dependent manner.

    Cell Death Dis 2012 19, 3:e351. Obatoclax Mesylate (GX15-070) purchased from Selleck.

     

    Upregulation of A1 is crucial for resistance to ABT-737. The role of different anti-apoptotic Bcl-2 factors in determining resistance to ABT-737 was investigated, comparing the pro-apoptotic effect of ABT-737, antimycin A and obatoclax on activated (filled circles) and non-activated (open circles) BM3.3 CD8 T cells. T-cell activation induced resistance to ABT-737 and to antimycin A, but not to obatoclax, demonstrating a crucial role of A1 in this phenomenon. Percentage of cells treated with DMSO-containing vehicle is given. Half maximal inhibitory concentration (IC50) and 95% confidence interval (95% CI) are reported in the table.

    Cell Death Dis 2012 3, e299. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • HUH6 cells (C-H) were incubated with and without 10 ng/ml TNF-α and obatoclax at 0.1, 0.3 uM. Fewer mitochondria with an intact membrane potential were observed in JC-1 staining when obatoclax and TNF-α were added to the culture. Reddish points indicate the aggregation of JC-1 in intact mitochondria, and missing of reddish points indicate the start of apoptosis.

    Exp Cell Res 2014 322, 217-25. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    Cell proliferation assays were carried out in SET-2 cells treated with increasing concentrations of NVP-BSK805 (empty triangles/solid line), obatoclax (filled squares/dotted line) or NVP-BSK805 in combination with a fixed obatoclax concentration of 700 nM (filled triangles/stippled line) for 72 hours.

     

     

    BMC Cancer 2011 11, 24. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • MEF cells were treated for  24 hours with the Bcl-2 antagonists  Obatoclax Mesylate at the indicated doses.Acute survival was monitored by replacing the drug-containing media with normal media and incubating the cells until visible colonies formed.Clonogenic survival is expressed relative to the numbers of colonies formed following 24 hours incubation in normal media(lacking drugs).

     

     

    Dr. Christine Hawkins of La Trobe University. Obatoclax Mesylate (GX15-070) purchased from Selleck.

    MDB-MA-231 cells were exposed to 30 μM cisplatin in the absence or in thepresence of 1 μM Obatoclax Mesylate .The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. Obatoclax Mesylate (GX15-070) purchased from Selleck.

  • Obataclax triggers cell death similarly in parental and ABT-737-resistant cells. Parental and ABT-R cells were treated with obataclax (Nalm-6 and Nalm-6 ABT-R: 10 uM; Reh and Reh ABT-R: 5 uM) for 18 h. (A) Cell viability was determined by trypan blue exclusion assay. (B) Mcl-1, NOXA, Bim, and b-actin as a loading control were analyzed by immunoblot. 

    Obatoclax Mesylate (GX15-070) purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with Ki of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.
Features Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.
Targets
Bcl-2 [1]
(Cell-free assay)
0.22 μM(Ki)
In vitro

Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. [1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. [2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KARPAS-45 M{Pme2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\WTYR7UUN3ME2wMlAxODB|MUeg{txO NVrTdGlMW0GQR1XS
SK-MEL-30 MkTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvEdnlKSzVyPUCuNFAxOzV3IN88US=> NWnXW4t1W0GQR1XS
NALM-6 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7TemQxUUN3ME2wMlAxODN3NjFOwG0> MUfTRW5ITVJ?
KYSE-450 NVrq[YdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoL6TWM2OD1yLkCwNFQ3QSEQvF2= M4X5PHNCVkeHUh?=
BHY NILJTWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMECwOlAyKM7:TR?= MULTRW5ITVJ?
GR-ST NX;3WphMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DlU2lEPTB;MD6wNFA3PDhizszN NH;sW2hUSU6JRWK=
786-0 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPIUZdKSzVyPUCuNFAxPzd4IN88US=> MVTTRW5ITVJ?
C-33-A M4Pzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVT1UHF4UUN3ME2wMlAxODh2ODFOwG0> MmLMV2FPT0WU
BHT-101 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwMECxNFYh|ryP M3fCXHNCVkeHUh?=
EB2 NXT4Zo54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{K3fWlEPTB;MD6wNFEyQCEQvF2= M4HjZXNCVkeHUh?=
G-361 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3SdlNKSzVyPUCuNFAyOjRizszN MnfiV2FPT0WU
KE-37 NYjEZ25nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fvemlEPTB;MD6wNFEzQCEQvF2= NVf6dZFNW0GQR1XS
MHH-PREB-1 NFG3OnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTaS5hKSzVyPUCuNFAyPCEQvF2= MUjTRW5ITVJ?
MCF7 M3jkcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLTfZFKSzVyPUCuNFAyPTlizszN M4niTHNCVkeHUh?=
LOUCY NWTkVVQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\q[WJ1UUN3ME2wMlAxOTd3IN88US=> MXLTRW5ITVJ?
EW-7 M2rzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjyTWM2OD1yLkCwNVc2KM7:TR?= MVnTRW5ITVJ?
KYSE-510 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVywXIdWUUN3ME2wMlAxOjN|IN88US=> NVzGNmVNW0GQR1XS
SK-MEL-3 NXXkWXcxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\qd2lEPTB;MD6wNFI3PCEQvF2= MofhV2FPT0WU
HAL-01 MorYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rmVGlEPTB;MD6wNFI6PyEQvF2= MkX3V2FPT0WU
HCC2998 MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjGU3VpUUN3ME2wMlAxOzN3IN88US=> NUfLd5JrW0GQR1XS
A375 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\RTWM2OD1yLkCwN|Uh|ryP NWS4bm5ZW0GQR1XS
MZ7-mel NFzs[nBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rpUWlEPTB;MD6wNFM6QSEQvF2= M1GwbHNCVkeHUh?=
SH-4 M2nlSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2W1XGlEPTB;MD6wNFQyPyEQvF2= M2LWSHNCVkeHUh?=
HT-144 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwMEC0N{DPxE1? MWDTRW5ITVJ?
KYSE-140 NUPMR4ZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mny5TWM2OD1yLkCwOFM2KM7:TR?= M17HU3NCVkeHUh?=
PSN1 NUnzOpNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf3TWM2OD1yLkCwOFY4KM7:TR?= M1TCeHNCVkeHUh?=
COLO-679 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\aZotKSzVyPUCuNFA1QThizszN NIXBNVBUSU6JRWK=
SW620 M3LHPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXr6fW5SUUN3ME2wMlAxPTFzIN88US=> NVvlc5F{W0GQR1XS
HGC-27 NVPPXnpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37pXWlEPTB;MD6wNFUzPCEQvF2= MnfPV2FPT0WU
IGROV-1 NUj0b2Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nVb2lEPTB;MD6wNFYh|ryP MXHTRW5ITVJ?
IGR-1 NVTKd49CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIe2UI9KSzVyPUCuNFA3ODFizszN MWXTRW5ITVJ?
EW-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfKNHhKSzVyPUCuNFA3PTFizszN M4Oy[nNCVkeHUh?=
769-P NVLnR|EyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4D6NmlEPTB;MD6wNFY4QCEQvF2= NV7OTJE6W0GQR1XS
HN MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwMEC2O|kh|ryP MVTTRW5ITVJ?
SIG-M5 NHTFRlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfrSpU1UUN3ME2wMlAxPzFizszN MoH4V2FPT0WU
IST-MEL1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\HTWM2OD1yLkCwPFE5KM7:TR?= M4DuSnNCVkeHUh?=
ST486 NFn4VWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlWwTWM2OD1yLkCwPFI2KM7:TR?= M2mwZXNCVkeHUh?=
ES7 M3\xVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwMEC4OFYh|ryP NWfzdlRjW0GQR1XS
GAK NUCxVmpiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwMEC4OFgh|ryP M1zpV3NCVkeHUh?=
BB30-HNC MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPuPYpKSzVyPUCuNFA5PThizszN NFXYdZZUSU6JRWK=
IPC-298 NV6yPZhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPyTWM2OD1yLkCwPVI4KM7:TR?= MlvtV2FPT0WU
NKM-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;QTWM2OD1yLkCwPVczKM7:TR?= MlTUV2FPT0WU
RKO M1vobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\MU2lEPTB;MD6wNVA1PCEQvF2= Mne1V2FPT0WU
ACN NFzqZ5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnoN3A2UUN3ME2wMlAyOTNzIN88US=> M13kfHNCVkeHUh?=
SW1417 NYXUVmpoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHyweZpKSzVyPUCuNFEzOjVizszN M{PMdHNCVkeHUh?=
SR NID5TYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3OTWM2OD1yLkCxNlM2KM7:TR?= NFPoW4dUSU6JRWK=
SNG-M MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTBwMEGzNVch|ryP MUPTRW5ITVJ?
CAL-12T NHrmZZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLKTJI2UUN3ME2wMlAyOzR4IN88US=> NWK5dWZ7W0GQR1XS
HSC-3 M4[2c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M120XWlEPTB;MD6wNVM2PSEQvF2= M4L1[XNCVkeHUh?=
DOHH-2 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1GwcmlEPTB;MD6wNVQyOiEQvF2= M4P2[XNCVkeHUh?=
NB69 NUGxU3B5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIfYeVZKSzVyPUCuNFE2PjVizszN NHfoPJdUSU6JRWK=
LC-2-ad M33EfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXuWoRKSzVyPUCuNFE2QDFizszN NUHNXWg4W0GQR1XS
RVH-421 MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWGyZXVKUUN3ME2wMlAyPjd2IN88US=> NFXCcnZUSU6JRWK=
TGW MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHR[3JKSzVyPUCuNFE4OzlizszN M2WxdnNCVkeHUh?=
HCC1569 M2jMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTBwMEG3PVch|ryP MkPUV2FPT0WU
CAL-85-1 NUP6XmtPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3nzZ2lEPTB;MD6wNVg{OiEQvF2= M1PWRnNCVkeHUh?=
RPMI-8402 M1;GOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3ZRpRKSzVyPUCuNFE5PThizszN NHrLPWtUSU6JRWK=
THP-1 MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLiPXM3UUN3ME2wMlAyQTl6IN88US=> NHrNVHpUSU6JRWK=
ONS-76 MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTBwMEKwN|Yh|ryP MUXTRW5ITVJ?
A2780 Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwMEKwO|kh|ryP NWrLOW43W0GQR1XS
RPMI-2650 M{P2OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HSSGlEPTB;MD6wNlI6PiEQvF2= M3rrNXNCVkeHUh?=
MEL-HO NGPsVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDLTWM2OD1yLkCyN|Q5KM7:TR?= NWmxOIlJW0GQR1XS
MC-CAR NG\QZ|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwMEKzOVYh|ryP MlfCV2FPT0WU
HSC-2 NE\PRoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTBwMEK0OlYh|ryP NWqzTppjW0GQR1XS
MEL-JUSO M{LCcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\RWHZuUUN3ME2wMlAzPDd|IN88US=> NWTiSHppW0GQR1XS
CAL-62 M1O2W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXJTWM2OD1yLkCyOlAzKM7:TR?= M3vWXHNCVkeHUh?=
DMS-273 Mm\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;3WZBCUUN3ME2wMlAzQDR5IN88US=> NHrye3lUSU6JRWK=
S-117 M4j4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fOOWlEPTB;MD6wNlkxPiEQvF2= MlzxV2FPT0WU
SUP-T1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWr5XGZlUUN3ME2wMlAzQTR7IN88US=> M4fXOHNCVkeHUh?=
MZ2-MEL NVHzRWxVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrFfXpKSzVyPUCuNFI6PTlizszN NIPuVXBUSU6JRWK=
KYSE-270 NGfXfo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3tTWM2OD1yLkCyPVc3KM7:TR?= MVfTRW5ITVJ?
CMK MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rUcGlEPTB;MD6wN|AzOyEQvF2= MX3TRW5ITVJ?
8505C NWnj[JJuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TXSWlEPTB;MD6wN|A1KM7:TR?= NVnLU|BpW0GQR1XS
NUGC-3 MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jveGlEPTB;MD6wN|A1QCEQvF2= MmHOV2FPT0WU
A101D NXvlNJVyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwMEOwOVUh|ryP NI\EVnlUSU6JRWK=
G-401 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnnZTWM2OD1yLkCzNFk{KM7:TR?= NFLsdmRUSU6JRWK=
OVCAR-8 M{DyfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjJTWM2OD1yLkCzNVA4KM7:TR?= NWW2Z2xKW0GQR1XS
IMR-5 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV[5XFZlUUN3ME2wMlA{OjR2IN88US=> NHzsXoNUSU6JRWK=
DoTc2-4510 NIPRS2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMEOzPVMh|ryP NVfud4ZKW0GQR1XS
HOS MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzL[oRrUUN3ME2wMlA{PDd|IN88US=> M17oWnNCVkeHUh?=
HEC-1 MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\iTWM2OD1yLkCzOlgh|ryP MnPqV2FPT0WU
SW756 MoW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXRTWM2OD1yLkCzPFIyKM7:TR?= NYrSVoI5W0GQR1XS
NCI-H64 NHLvOWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzGWFJKSzVyPUCuNFM5PDJizszN NF36dGpUSU6JRWK=
EW-16 NEXyWpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LZN2lEPTB;MD6wN|kxQSEQvF2= Mk\NV2FPT0WU
CAL-51 NWT3SnZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLnSGFKSzVyPUCuNFQxODVizszN NE\HPZNUSU6JRWK=
KYSE-150 MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTBwMESwNVEh|ryP MmjFV2FPT0WU
SW1710 NHGxNlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\GSWNkUUN3ME2wMlA1ODF6IN88US=> MknHV2FPT0WU
HuP-T4 NVntW3lCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTBwMESxNVgh|ryP NHXNT|FUSU6JRWK=
LB373-MEL-D MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mor4TWM2OD1yLkC0NlMzKM7:TR?= MnOzV2FPT0WU
EW-13 NHzZe|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[3d5NKSzVyPUCuNFQ1ODZizszN MlXEV2FPT0WU
HT-29 NFHGVJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XkNmlEPTB;MD6wOFQ6KM7:TR?= NWPtS2ZMW0GQR1XS
SCC-25 M4H1U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PEWmlEPTB;MD6wOFQ6PCEQvF2= NHTqUldUSU6JRWK=
REH NInpSIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLjTWM2OD1yLkC0OlM2KM7:TR?= M1nCS3NCVkeHUh?=
L-363 MkDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfrTWM2OD1yLkC0Olc6KM7:TR?= NX7he2pKW0GQR1XS
NCI-H1770 NYLjS4gxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL1NGI2UUN3ME2wMlA1Pjl5IN88US=> M165cXNCVkeHUh?=
CHL-1 MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwMES4OVch|ryP MWPTRW5ITVJ?
ES1 M4r5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFL3c4VKSzVyPUCuNFQ5QDVizszN MVzTRW5ITVJ?
SCC-15 M17hWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGj3NW9KSzVyPUCuNFQ6ODJizszN NV7lO5BDW0GQR1XS
MRK-nu-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHZeplKSzVyPUCuNFQ6OzZizszN MkDQV2FPT0WU
PF-382 MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\me2lEPTB;MD6wOFk{QSEQvF2= MWLTRW5ITVJ?
COLO-680N NFnKblJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUS0[|c2UUN3ME2wMlA2ODR5IN88US=> MXnTRW5ITVJ?
LK-2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\C[IVYUUN3ME2wMlA2ODZ|IN88US=> M36zdXNCVkeHUh?=
NCI-H2342 M3fOS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTBwMEWxNVch|ryP NH3vd4VUSU6JRWK=
HMV-II NHrVSY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWKwTXNzUUN3ME2wMlA2OjN7IN88US=> M4r4NnNCVkeHUh?=
PC-14 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn21TWM2OD1yLkC1NlUzKM7:TR?= M{jwZ3NCVkeHUh?=
COLO-320-HSR MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmSwTWM2OD1yLkC1Nlg6KM7:TR?= Mn\iV2FPT0WU
697 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;Jem9HUUN3ME2wMlA2OzJ|IN88US=> NIn0fVFUSU6JRWK=
NEC8 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\OSZlKSzVyPUCuNFU2QSEQvF2= NH7DO2RUSU6JRWK=
LCLC-97TM1 NYj0VHRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmi0TWM2OD1yLkC1OVk1KM7:TR?= NULiRYpFW0GQR1XS
Daoy MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jLSGlEPTB;MD6wOVYyPiEQvF2= Ml\DV2FPT0WU
ETK-1 M{XyNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rjS2lEPTB;MD6wOVY4OiEQvF2= NULtZ3lNW0GQR1XS
A388 NYLkeZRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMEW2PVUh|ryP MUTTRW5ITVJ?
COLO-205 M1fLeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXixRZhlUUN3ME2wMlA2PzF4IN88US=> NWDZWFFSW0GQR1XS
SK-PN-DW NYrTWmR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmjUTWM2OD1yLkC1O|I6KM7:TR?= MUTTRW5ITVJ?
SF268 M{PhOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXPJR|UxRTBwMEW3OVYh|ryP Ml:2V2FPT0WU
OCI-AML2 MmjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrtTWM2OD1yLkC1O|c4KM7:TR?= M{TRSnNCVkeHUh?=
GAMG MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTBwMEW4JO69VQ>? MWHTRW5ITVJ?
BCPAP NVTPVY5{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\YT2lEPTB;MD6wOVg6OiEQvF2= MXzTRW5ITVJ?
BC-1 M2nLcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYT5NVhXUUN3ME2wMlA3ODJ{IN88US=> M3HPUXNCVkeHUh?=
IA-LM MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfNTWM2OD1yLkC2NFU{KM7:TR?= MV7TRW5ITVJ?
NCI-H1299 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzBSI9YUUN3ME2wMlA3OTNizszN M{CzdHNCVkeHUh?=
COR-L23 MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fmVWlEPTB;MD6wOlE{PCEQvF2= M4TsXnNCVkeHUh?=
KYSE-180 MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\Hb4k5UUN3ME2wMlA3OTR{IN88US=> NUn4RpRQW0GQR1XS
LOXIMVI MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLsTWM2OD1yLkC2NVg5KM7:TR?= NH[0SZRUSU6JRWK=
BL-41 NWjpPFN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Ps[mlEPTB;MD6wOlIyQSEQvF2= MonIV2FPT0WU
BL-70 MlTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXpTWM2OD1yLkC2N|AzKM7:TR?= M3S3OHNCVkeHUh?=
NOS-1 M4[0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrJVZFKSzVyPUCuNFY1OTFizszN NIDGdGtUSU6JRWK=
NB13 NYnnW|g6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:yb2lEPTB;MD6wOlQzOSEQvF2= NVi3SIRjW0GQR1XS
CAL-27 NVyyXVF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\Ec2FKSzVyPUCuNFY1PjRizszN MoLNV2FPT0WU
CA46 MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTBwME[1N|ch|ryP NHPHfnBUSU6JRWK=
SW962 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTBwME[1Olkh|ryP NGr3RplUSU6JRWK=
NCI-H226 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1uwdWlEPTB;MD6wOlY{OiEQvF2= MV7TRW5ITVJ?
KYSE-70 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTBwME[5OFUh|ryP MUPTRW5ITVJ?
Daudi M2XBOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rKb2lEPTB;MD6wO|A5OSEQvF2= NFPyR2ZUSU6JRWK=
SW626 MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULaWlk6UUN3ME2wMlA4OjB2IN88US=> NX;ON2Q5W0GQR1XS
ESS-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HSeGlEPTB;MD6wO|I1PiEQvF2= NHmz[GNUSU6JRWK=
YT NV3T[lA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTvTWM2OD1yLkC3N|Q2KM7:TR?= MlHBV2FPT0WU
P12-ICHIKAWA NY\QWZJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml[2TWM2OD1yLkC3N|Q6KM7:TR?= MV;TRW5ITVJ?
BxPC-3 Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFX5d5ZKSzVyPUCuNFc1PThizszN MXfTRW5ITVJ?
CTV-1 NHvNSpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e4RmlEPTB;MD6wO|UyPyEQvF2= MXXTRW5ITVJ?
MLMA NUOzXJozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnq3TWM2OD1yLkC3OVM1KM7:TR?= NEToR|NUSU6JRWK=
WSU-NHL MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojlTWM2OD1yLkC3OVU1KM7:TR?= MlvxV2FPT0WU
CTB-1 M3TINGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwMEe1PFgh|ryP NHfkZ3lUSU6JRWK=
MMAC-SF NHi3[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwMEe2Olgh|ryP M1HkPHNCVkeHUh?=
8-MG-BA M3nrd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwMEe4NFEh|ryP M1XoT3NCVkeHUh?=
NCI-H358 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;re2lEPTB;MD6wO|g4QSEQvF2= NH3CTGhUSU6JRWK=
BFTC-905 NEjmOFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fG[GlEPTB;MD6wO|kxQSEQvF2= MoLPV2FPT0WU
NCI-H727 MnjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXq0cI95UUN3ME2wMlA5ODV|IN88US=> MoPLV2FPT0WU
CHP-212 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTBwMEiwPVUh|ryP NGT3O3ZUSU6JRWK=
HOP-62 NILmUGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMEiyOFUh|ryP MlfvV2FPT0WU
CESS MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrHTWM2OD1yLkC4NlY6KM7:TR?= MUnTRW5ITVJ?
HuCCT1 M3\JSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHCUFRKSzVyPUCuNFg{OzNizszN NF7xN|RUSU6JRWK=
DEL MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMEizOFch|ryP MlPsV2FPT0WU
5637 NGrQVpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlP0TWM2OD1yLkC4N|Y4KM7:TR?= NEfZRXRUSU6JRWK=
RS4-11 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwMEi0PVch|ryP M2fkRXNCVkeHUh?=
KURAMOCHI M1HaOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMEi1NFkh|ryP MXfTRW5ITVJ?
A427 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwMEi1NVIh|ryP M13pTnNCVkeHUh?=
A3-KAW M3;VXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlO5TWM2OD1yLkC4OVY3KM7:TR?= MmPsV2FPT0WU
LS-123 NIK2VIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHO[FJKSzVyPUCuNFg4OTlizszN M4nPVXNCVkeHUh?=
LoVo Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDFTWM2OD1yLkC4O|Ih|ryP MXXTRW5ITVJ?
PA-1 NYr6XFNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXUfpJKSzVyPUCuNFg4PjlizszN MXTTRW5ITVJ?
CP50-MEL-B MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITiUVdKSzVyPUCuNFg4QTNizszN MUTTRW5ITVJ?
A431 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwMEi4NFEh|ryP NUK4[pJpW0GQR1XS
HCT-116 NIfMUGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFj2UINKSzVyPUCuNFg5ODJizszN NUSzU5lQW0GQR1XS
A4-Fuk MkDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvZXodKSzVyPUCuNFg6PDdizszN M2HNVXNCVkeHUh?=
RPMI-6666 MoDVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\KTWM2OD1yLkC4PVY4KM7:TR?= NULuVIpxW0GQR1XS
Calu-6 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPTTWM2OD1yLkC5NFI6KM7:TR?= NV3ueZFSW0GQR1XS
KMOE-2 MmDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moq5TWM2OD1yLkC5NFM6KM7:TR?= MljrV2FPT0WU
A704 MmfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoDtTWM2OD1yLkC5NVUh|ryP NF7QfXJUSU6JRWK=
HO-1-N-1 NEnmR2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3LhPWlEPTB;MD6wPVI1QSEQvF2= MkHKV2FPT0WU
NCI-H2122 NHrtS5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{\0T2lEPTB;MD6wPVM4QCEQvF2= NE\qVpZUSU6JRWK=
U-698-M NU\qR3BGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjOTWM2OD1yLkC5OFA6KM7:TR?= MYjTRW5ITVJ?
IST-SL2 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTmW3hWUUN3ME2wMlA6PDZ6IN88US=> NX7jNJhMW0GQR1XS
TE-10 MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4T3O2lEPTB;MD6wPVU5PCEQvF2= MWjTRW5ITVJ?
PANC-03-27 MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XQR2lEPTB;MD6wPVY4OSEQvF2= MVjTRW5ITVJ?
KYSE-410 MkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;qe5RKSzVyPUCuNFk4QTdizszN MX;TRW5ITVJ?
TE-8 Mne2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPFSmVKSzVyPUCuNFk5QDVizszN M1;BSHNCVkeHUh?=
MN-60 MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPqWZFwUUN3ME2wMlA6QDl5IN88US=> M{jY[3NCVkeHUh?=
NCI-H460 MnjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljuTWM2OD1yLkGwNFkh|ryP NEjFRnNUSU6JRWK=
LB771-HNC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwMUCyOVUh|ryP NIPKd|BUSU6JRWK=
ES4 NIPIZoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{[0SmlEPTB;MD6xNFI3PCEQvF2= M4j5SXNCVkeHUh?=
HUTU-80 MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjRUHJWUUN3ME2wMlExOzZ3IN88US=> NYf4Z|BzW0GQR1XS
647-V MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMUC0NFgh|ryP NUDkNlZtW0GQR1XS
HTC-C3 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTBwMUC0N|Ih|ryP M37DeHNCVkeHUh?=
NTERA-S-cl-D1 NV7kVVR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXO[nZTUUN3ME2wMlExPDR6IN88US=> Mk\QV2FPT0WU
A2058 NGLQOVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrVTWM2OD1yLkGwOlU2KM7:TR?= NHrRWFVUSU6JRWK=
MZ1-PC MkniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7CTWM2OD1yLkGwPFMh|ryP NIX1OohUSU6JRWK=
J82 MlraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XNOWlEPTB;MD6xNFg5PCEQvF2= MlfhV2FPT0WU
ARH-77 NH65NnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz2TWM2OD1yLkGxJO69VQ>? NEG2UJlUSU6JRWK=
Ca9-22 NI\POVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXiRmJKSzVyPUCuNVEyOjhizszN NFj5UnJUSU6JRWK=
NCI-H1648 M3rGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jwfWlEPTB;MD6xNVI5PiEQvF2= MmPvV2FPT0WU
MC116 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1W1W2lEPTB;MD6xNVM{PyEQvF2= NUDKWXZJW0GQR1XS
EoL-1-cell MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nSbGlEPTB;MD6xNVQ3PyEQvF2= NH\lUHVUSU6JRWK=
PANC-10-05 MoLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUH1PVR6UUN3ME2wMlEyPDlzIN88US=> MYXTRW5ITVJ?
SF539 NX\QUYpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIOyenJKSzVyPUCuNVE3OTZizszN MYDTRW5ITVJ?
ES8 NGjmW|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjNR3FKSzVyPUCuNVE3OzNizszN MnXtV2FPT0WU
NCI-H810 NHHCVIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTNNWNRUUN3ME2wMlEyPjZ2IN88US=> MnuyV2FPT0WU
J-RT3-T3-5 NVLXWoExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LITmlEPTB;MD6xNVc2KM7:TR?= MWTTRW5ITVJ?
NY NEm0OplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknLTWM2OD1yLkGxPFE4KM7:TR?= NE[2bnlUSU6JRWK=
NCI-SNU-1 M3rUXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwMUKxOFgh|ryP MX3TRW5ITVJ?
EFM-19 M3eycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMUKzO|Qh|ryP MnmxV2FPT0WU
HCC1806 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17pfWlEPTB;MD6xNlM5OyEQvF2= MlmxV2FPT0WU
HCE-T MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjve21KSzVyPUCuNVI2OzFizszN M4\JVHNCVkeHUh?=
HT-1376 NWDXXXozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DhfWlEPTB;MD6xNlY3QCEQvF2= MmXvV2FPT0WU
BE-13 M170[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHT0O2NKSzVyPUCuNVI5PjZizszN NWHLbGc3W0GQR1XS
NCI-H520 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTBwMUK4Olch|ryP M4TRVnNCVkeHUh?=
SK-MES-1 NHm3PVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH3XIpKSzVyPUCuNVI6OTNizszN NWLnNWZ{W0GQR1XS
SNU-423 M{e0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETVTWVKSzVyPUCuNVI6OTRizszN NVvRNZhrW0GQR1XS
Ramos-2G6-4C10 MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvGTWM2OD1yLkGyPVE3KM7:TR?= M{TF[HNCVkeHUh?=
EW-18 NX\PNmdDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwMUOwNlYh|ryP NVqyS3doW0GQR1XS
NCI-H2087 NXHUN3BOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X0V2lEPTB;MD6xN|AzPyEQvF2= NVfUXY82W0GQR1XS
COLO-792 MnfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUPJR|UxRTBwMUOxOlUh|ryP NW\kV3ZHW0GQR1XS
QIMR-WIL M1;4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLWTWM2OD1yLkGzNlI{KM7:TR?= M4PFVHNCVkeHUh?=
ACHN NUfWN3R7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXJ[GU{UUN3ME2wMlE{OjR5IN88US=> MXnTRW5ITVJ?
RPMI-8866 NXHMUZRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHG5XYxKSzVyPUCuNVMzPjFizszN MkfqV2FPT0WU
SK-LU-1 NFfjPIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTBwMUO0OFkh|ryP Mn7yV2FPT0WU
SK-UT-1 Mn;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwMUO2Nlgh|ryP NHXZWIVUSU6JRWK=
MFE-296 Mn3ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1;YU2lEPTB;MD6xN|g3PCEQvF2= NIT2cYRUSU6JRWK=
RD NIDqWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrwdIJjUUN3ME2wMlE{QTl5IN88US=> MlLIV2FPT0WU
LS-411N NVvVem9VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjrcHZKSzVyPUCuNVQzQTVizszN NIHSUGxUSU6JRWK=
NCI-H747 NUjYdlRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMUSzJO69VQ>? MkexV2FPT0WU
ES6 M{iyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfhdVRKSzVyPUCuNVQ{PiEQvF2= M1TsU3NCVkeHUh?=
TE-1 M161R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzKTWM2OD1yLkG0OFA4KM7:TR?= M3v5SnNCVkeHUh?=
SJSA-1 NX\1Z29HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMUS3NFch|ryP MWLTRW5ITVJ?
NCI-H1355 M2PkSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfJZ4RHUUN3ME2wMlE2Ojl|IN88US=> NHXkboZUSU6JRWK=
HEL MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7aSmdwUUN3ME2wMlE2PDR5IN88US=> NFnEV|NUSU6JRWK=
639-V MlGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfodJU6UUN3ME2wMlE2PTl4IN88US=> NYXmTWpVW0GQR1XS
AN3-CA NGPuXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXG5XIx{UUN3ME2wMlE2PjN7IN88US=> MUDTRW5ITVJ?
SK-MEL-2 M4PBXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorlTWM2OD1yLkG1OlY5KM7:TR?= MmflV2FPT0WU
SW872 NWfLeoxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLFTWM2OD1yLkG2NFQzKM7:TR?= M{TtWXNCVkeHUh?=
DU-4475 NVXiXoNKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnyTHY5UUN3ME2wMlE3OTZ{IN88US=> M4fnNHNCVkeHUh?=
YKG-1 NETF[ZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULieHFoUUN3ME2wMlE3Ojd|IN88US=> NXrjcYV4W0GQR1XS
GT3TKB NVjZfnNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TDUmlEPTB;MD6xOlI5OyEQvF2= M3PCcHNCVkeHUh?=
GB-1 MlLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMU[0NlQh|ryP MoXRV2FPT0WU
KARPAS-422 M{jMT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\qW2lEPTB;MD6xOlU4PCEQvF2= NISydo1USU6JRWK=
ATN-1 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITxSVVKSzVyPUCuNVY3PTZizszN Mkj2V2FPT0WU
HLE M2ixOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFT5N3FKSzVyPUCuNVY5PzdizszN NWfhZmF2W0GQR1XS
D-542MG MnK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zFS2lEPTB;MD6xOlk5PiEQvF2= NF60bpZUSU6JRWK=
EB-3 M2faZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\oSIduUUN3ME2wMlE4OzFizszN MULTRW5ITVJ?
HCC1143 MljOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTic3dKSzVyPUCuNVc{QTZizszN MVTTRW5ITVJ?
DJM-1 NVr5[pBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1fOZWlEPTB;MD6xO|Q2OSEQvF2= NYThUG1WW0GQR1XS
BT-474 NHPkZppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3HRnA1UUN3ME2wMlE4PDh7IN88US=> MW\TRW5ITVJ?
BB65-RCC NEPNVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTBwMUe1OFUh|ryP MYXTRW5ITVJ?
NCI-H292 NIniVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwMUe2NFEh|ryP MXrTRW5ITVJ?
MKN28 NFLwZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXFU3RKSzVyPUCuNVc3PTNizszN M13NfnNCVkeHUh?=
TK10 MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTBwMUe3NFIh|ryP M2T6NnNCVkeHUh?=
TYK-nu MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTBwMUe5OFkh|ryP MXPTRW5ITVJ?
8305C M3;Lcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGH3R4VKSzVyPUCuNVc6PzFizszN NY\5PHFtW0GQR1XS
MV-4-11 M2GxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7hb4FKSzVyPUCuNVc6PzdizszN MlvDV2FPT0WU
NCI-H522 NEDtSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HTRWlEPTB;MD6xPFA6PCEQvF2= MoXhV2FPT0WU
Hs-578-T NEfVNVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG[zSGRKSzVyPUCuNVgzQTJizszN MXzTRW5ITVJ?
LCLC-103H NYS5eXhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwMUi1Nlch|ryP M{DoN3NCVkeHUh?=
MHH-ES-1 NFjyVFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjMRYFKSzVyPUCuNVg3OjlizszN M1zIeXNCVkeHUh?=
NCI-H441 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTBwMUmxOFgh|ryP MX\TRW5ITVJ?
AM-38 Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTBwMUmyNlUh|ryP MlfGV2FPT0WU
SW1783 M4rFZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwMUmzNFUh|ryP MmTGV2FPT0WU
SK-HEP-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTBwMUm2N|ch|ryP M1fydnNCVkeHUh?=
OAW-28 NV\HcYJYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTBwMkCxO|gh|ryP NXT3fY1WW0GQR1XS
TE-15 M4nHOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUSzV5dWUUN3ME2wMlIxOjV{IN88US=> NFnlXY9USU6JRWK=
HCE-4 NVPBSVUyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwMkCyPFQh|ryP MlnTV2FPT0WU
JiyoyeP-2003 M33XWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYKxZmd2UUN3ME2wMlIxOzN4IN88US=> NHz5O4tUSU6JRWK=
OVCAR-4 Mn\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELHSJBKSzVyPUCuNlA3OjhizszN NUPNPHpjW0GQR1XS
SNU-449 NYDYRot7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG0TWM2OD1yLkKwO|k4KM7:TR?= NXTr[nZIW0GQR1XS
SBC-5 NEPTS|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPOTWM2OD1yLkKxNlE2KM7:TR?= NH60VnRUSU6JRWK=
T84 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\3Umh6UUN3ME2wMlIyOjR6IN88US=> M{LFd3NCVkeHUh?=
LP-1 NGHtd|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTBwMkGzNFIh|ryP MUHTRW5ITVJ?
MG-63 NXTKUYdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwMkGzPFIh|ryP MWLTRW5ITVJ?
OAW-42 NHL2dHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3PyNWlEPTB;MD6yNVQ4QCEQvF2= MVzTRW5ITVJ?
L-540 NXu1eXZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfoTWM2OD1yLkKxOVk5KM7:TR?= NFHFUG1USU6JRWK=
RH-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYfVU5I6UUN3ME2wMlIzOjR{IN88US=> NIPmOY1USU6JRWK=
HCT-15 MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnDdIJEUUN3ME2wMlIzPDh2IN88US=> NFS1WGRUSU6JRWK=
OCUB-M MmroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4C3c2lEPTB;MD6yNlQ5QCEQvF2= NWraSW1IW0GQR1XS
GP5d NIDsWGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fLc2lEPTB;MD6yNlUzQCEQvF2= MYHTRW5ITVJ?
NCI-H2030 M{m4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\qTWM2OD1yLkKyO|M1KM7:TR?= MXvTRW5ITVJ?
ML-2 NXvxcXh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\kfWZKSzVyPUCuNlI5QDlizszN NXz3RoppW0GQR1XS
CAL-39 NUDhT|BzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\JTWM2OD1yLkKyPVM3KM7:TR?= MmDHV2FPT0WU
MIA-PaCa-2 M2nwOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LJTGlEPTB;MD6yN|I5PyEQvF2= NWHnclBbW0GQR1XS
TE-9 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWG5VHU1UUN3ME2wMlI{OzJizszN NGC4W5VUSU6JRWK=
LB2518-MEL Mni2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwMkOzO|Ih|ryP NYiwVZM5W0GQR1XS
DB NHG3VY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nINWlEPTB;MD6yN|Q{QCEQvF2= MmrHV2FPT0WU
NCI-H596 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYq1dVhHUUN3ME2wMlI{PTdzIN88US=> NYDTZ4E6W0GQR1XS
SW1990 NF;2fJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonTTWM2OD1yLkKzPVQ3KM7:TR?= M{LpNXNCVkeHUh?=
P30-OHK NEH5TFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\6TVZKSzVyPUCuNlQxPSEQvF2= NIW3UnFUSU6JRWK=
ALL-PO MmnYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILvRmtKSzVyPUCuNlQyPjlizszN NIHEXJJUSU6JRWK=
Saos-2 NXjVbZhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PNPGlEPTB;MD6yOFU4OSEQvF2= NEHI[ZJUSU6JRWK=
MFH-ino M2n3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TXVWlEPTB;MD6yOFY6OiEQvF2= NI\QRWZUSU6JRWK=
OE33 NIS0[YZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37a[2lEPTB;MD6yOVEyKM7:TR?= MljhV2FPT0WU
Calu-3 NWXU[YhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTBwMkWyPVch|ryP Mn3VV2FPT0WU
HT MmrNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn\yTWM2OD1yLkK1OlIyKM7:TR?= MoD2V2FPT0WU
LXF-289 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMkW5PFQh|ryP MnfUV2FPT0WU
KGN MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\4eWlKSzVyPUCuNlYxQDlizszN NXLo[IExW0GQR1XS
NCI-H1417 MnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPvTWM2OD1yLkK2OVI1KM7:TR?= M2PS[HNCVkeHUh?=
SF126 NWPTSFFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zVdmlEPTB;MD6yO|MxOiEQvF2= M1zUbnNCVkeHUh?=
SAS NFnDOI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{D0[GlEPTB;MD6yO|MxQCEQvF2= NV7SZndMW0GQR1XS
22RV1 M3XSN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwMkezO|gh|ryP MY\TRW5ITVJ?
GI-1 NYLuR|MxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPuTlFKSzVyPUCuNlc1QDdizszN NW[3W2lSW0GQR1XS
ES3 NWDWUIpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoO5TWM2OD1yLkK3O|Y{KM7:TR?= M{Hm[HNCVkeHUh?=
NB1 NIfG[Y5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3LTWM2OD1yLkK3PFc3KM7:TR?= NYLaepF{W0GQR1XS
NCI-H650 MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXLCOHh4UUN3ME2wMlI5OzB{IN88US=> MV7TRW5ITVJ?
IST-MES1 NUXocYt[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjGXXBKSzVyPUCuNlg2PTRizszN MoTHV2FPT0WU
UM-UC-3 M{PGWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDwfFJNUUN3ME2wMlI6OTRizszN Mo[yV2FPT0WU
CAL-120 NFf5cJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnK5TWM2OD1yLkK5OlMyKM7:TR?= MXrTRW5ITVJ?
UACC-62 NXPBd4hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:5Z2lEPTB;MD6zNFI1OSEQvF2= NYfydmxPW0GQR1XS
TE-11 M4H3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTETWM2OD1yLkOwNlQ6KM7:TR?= MYXTRW5ITVJ?
MKN1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlLvTWM2OD1yLkOwN|Yh|ryP NUm5R2llW0GQR1XS
KS-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojjTWM2OD1yLkOwOVI3KM7:TR?= MkH0V2FPT0WU
GCIY NIfkTHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrFTWM2OD1yLkOxNFAzKM7:TR?= MVjTRW5ITVJ?
OVCAR-5 M4X0Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjyPWtQUUN3ME2wMlMyOTB4IN88US=> MWnTRW5ITVJ?
U-266 NU\xOXZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTBwM{GxOFch|ryP NYnQZploW0GQR1XS
Calu-1 NGC5c4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DFVmlEPTB;MD6zNVI5QSEQvF2= Mlz2V2FPT0WU
SK-LMS-1 M4P5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwM{G0Nlkh|ryP MV3TRW5ITVJ?
COLO-741 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1e3XGlEPTB;MD6zNVYyPCEQvF2= M3yz[XNCVkeHUh?=
RPMI-8226 NFXLTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjrd412UUN3ME2wMlMyPjRzIN88US=> NInvTW1USU6JRWK=
KM12 NXuxe2tJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LQRWlEPTB;MD6zNVg{KM7:TR?= M2\qV3NCVkeHUh?=
NMC-G1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTBwM{G4OkDPxE1? MkHLV2FPT0WU
SJRH30 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnviTWM2OD1yLkOyNFUzKM7:TR?= MYXTRW5ITVJ?
COR-L105 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\TTWM2OD1yLkOyNlE5KM7:TR?= NY\FWGZoW0GQR1XS
IM-9 M3;VdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHhW5J5UUN3ME2wMlM{ODJzIN88US=> M17yO3NCVkeHUh?=
TE-12 NGXVZXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwM{OzNVch|ryP M{TW[HNCVkeHUh?=
KG-1 NGj5XXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzBc2RKSzVyPUCuN|M1OzJizszN MonmV2FPT0WU
U251 M2PxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPqdGlKSzVyPUCuN|M1PTZizszN MortV2FPT0WU
EFO-27 MoTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;CTWM2OD1yLkOzPVUyKM7:TR?= MmnhV2FPT0WU
EW-24 Mn22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFfafWpKSzVyPUCuN|M6QDRizszN MoS1V2FPT0WU
SF295 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVjmRoF4UUN3ME2wMlM{QTl7IN88US=> NFfxRWtUSU6JRWK=
MC-IXC MlzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M176ZWlEPTB;MD6zOFUh|ryP Mmn5V2FPT0WU
NCI-H2405 NIixZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTUTWM2OD1yLkO0O|MzKM7:TR?= MoPUV2FPT0WU
NCI-H2009 Mne3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3TemJKSzVyPUCuN|Q4OzlizszN MnvhV2FPT0WU
LB1047-RCC MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jLPGlEPTB;MD6zOVgyPSEQvF2= MojoV2FPT0WU
KNS-81-FD NXzyd2hOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13RdGlEPTB;MD6zOlY3PyEQvF2= M175TXNCVkeHUh?=
HOP-92 M{Dq[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfZTWM2OD1yLkO2PFMh|ryP MV\TRW5ITVJ?
L-428 MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PVfGlEPTB;MD6zO|AyPiEQvF2= NF[wUnZUSU6JRWK=
C3A NYnXOoR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonLTWM2OD1yLkO3N|c6KM7:TR?= NF;QOHZUSU6JRWK=
NCI-H1792 NUfXdlB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPTWoNGUUN3ME2wMlM4PjV3IN88US=> MXHTRW5ITVJ?
HuH-7 NVHDXINET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXIcFlKSzVyPUCuN|c6OSEQvF2= MmW5V2FPT0WU
AGS M2qxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTBwM{i2N|gh|ryP MkHrV2FPT0WU
HT-1197 NWHa[GJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\vTWM2OD1yLkO5OFYh|ryP M4O3UnNCVkeHUh?=
CGTH-W-1 NFSzTGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jyN2lEPTB;MD6zPVkyOyEQvF2= M1faNHNCVkeHUh?=
KNS-42 NH\NbVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mli0TWM2OD1yLkSwNFQ2KM7:TR?= MoPyV2FPT0WU
HuO-3N1 M{e5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwNECwOVUh|ryP MW\TRW5ITVJ?
VMRC-RCZ MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVm3SXZJUUN3ME2wMlQxOzB|IN88US=> MU\TRW5ITVJ?
SW954 M1HDZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXZTWM2OD1yLkSwN|M2KM7:TR?= M3HLOHNCVkeHUh?=
MES-SA MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;RSm9vUUN3ME2wMlQxPTB3IN88US=> MmTnV2FPT0WU
Ca-Ski NInvU3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTBwNEC1NlQh|ryP NHr6XJJUSU6JRWK=
SW13 M2DPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PCZ2lEPTB;MD60NFYzPiEQvF2= NHXm[XZUSU6JRWK=
NCI-H1437 NH[yOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF7EXJFKSzVyPUCuOFA5ODVizszN NXj6VXNWW0GQR1XS
U-118-MG MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nkfmlEPTB;MD60NFkxPCEQvF2= NUXmWodbW0GQR1XS
NCI-H1734 MkS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\Sc2JKSzVyPUCuOFIxOTNizszN MmOxV2FPT0WU
HDLM-2 NVnqbolLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwNEKwN|Mh|ryP M3P0e3NCVkeHUh?=
AU565 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwNEK0Olgh|ryP MUnTRW5ITVJ?
FADU NUO3d2IzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjhTWM2OD1yLkSyOlQ6KM7:TR?= Ml;6V2FPT0WU
OS-RC-2 NGrnUFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PSXmlEPTB;MD60N|A5OyEQvF2= NYe1UGJHW0GQR1XS
CAMA-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MofUTWM2OD1yLkSzOlI3KM7:TR?= MkXIV2FPT0WU
MONO-MAC-6 NUDlOYxkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFOwRmlKSzVyPUCuOFM5PDlizszN NYHoOnVmW0GQR1XS
LB831-BLC Mme4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvCclF6UUN3ME2wMlQ1OzdzIN88US=> MoPjV2FPT0WU
SW982 NHX4OHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwNES1Nlgh|ryP NWjBXnJEW0GQR1XS
SCC-3 M4nS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;wTWM2OD1yLkS0OVc6KM7:TR?= NV[xVVNwW0GQR1XS
C32 NX3NXZJzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TGWmlEPTB;MD60OVIzQSEQvF2= M1n5[HNCVkeHUh?=
BFTC-909 NFOxVXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGWycHdKSzVyPUCuOFUzQTlizszN MWfTRW5ITVJ?
MEG-01 M3ztT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjkS2lqUUN3ME2wMlQ2Ozd|IN88US=> M4PLbnNCVkeHUh?=
M14 NYDUPG1PT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mor2TWM2OD1yLkS1PVc6KM7:TR?= M4fNTXNCVkeHUh?=
MPP-89 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fuXWlEPTB;MD60OlI2PiEQvF2= MlHjV2FPT0WU
HCC1937 M3HncWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXntephIUUN3ME2wMlQ3Ozh2IN88US=> NWT5O4EyW0GQR1XS
SW837 NEjOO2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPG[mFKSzVyPUCuOFY4OjJizszN NGTBW3dUSU6JRWK=
DU-145 NVzOU2ZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTBwNE[3Nlkh|ryP MVXTRW5ITVJ?
LB996-RCC NFXtO41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3RTWM2OD1yLkS3NFU1KM7:TR?= NX7pUXNDW0GQR1XS
C8166 MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwNEe0JO69VQ>? NGjIeYpUSU6JRWK=
MOLT-4 NVnqTo1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH75Oo9KSzVyPUCuOFc4OzRizszN MlnTV2FPT0WU
DMS-53 MkW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7UTWM2OD1yLkS3PFA6KM7:TR?= M4HCcXNCVkeHUh?=
TE-5 NI[yWFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmPGTWM2OD1yLkS4N|A2KM7:TR?= MWjTRW5ITVJ?
KYSE-520 NIrIZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTBwNEizOFMh|ryP MlPvV2FPT0WU
Detroit562 NYnRR3V[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwNEi4OkDPxE1? MVXTRW5ITVJ?
SIMA MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFi5bYFKSzVyPUCuOFk1OTdizszN MWDTRW5ITVJ?
NCI-H1651 NGHQc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX31N4pZUUN3ME2wMlQ6PjdizszN NHjDWVdUSU6JRWK=
HCC1599 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[1TWM2OD1yLkS5PVU2KM7:TR?= M3PNZ3NCVkeHUh?=
ABC-1 MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nDOGlEPTB;MD61NFQ6PiEQvF2= NH2xN4ZUSU6JRWK=
CAL-33 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwNUC4OFQh|ryP Mlu1V2FPT0WU
OPM-2 M4PaSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTBwNUC5N|ch|ryP MkfSV2FPT0WU
RPMI-7951 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPHPZJSUUN3ME2wMlUxQTV5IN88US=> NV\Cd|FrW0GQR1XS
HT-1080 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrITWM2OD1yLkWxNVE6KM7:TR?= MkixV2FPT0WU
LC4-1 M4XWR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTBwNUG0NFMh|ryP NHfzTVlUSU6JRWK=
OVCAR-3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFOyTmdKSzVyPUCuOVE2PyEQvF2= M3fre3NCVkeHUh?=
CAPAN-1 M2DPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MomyTWM2OD1yLkWyNlg5KM7:TR?= M3r6VXNCVkeHUh?=
SK-OV-3 M1L5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTBwNUK0N|Qh|ryP NYjNWZNYW0GQR1XS
HuP-T3 NXzucnlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jLcWlEPTB;MD61NlgzPyEQvF2= NGLySZVUSU6JRWK=
NCI-H838 M3[3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTpdWtzUUN3ME2wMlUzQDR7IN88US=> MmLDV2FPT0WU
K5 NGLJRZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYr6XJlTUUN3ME2wMlU{OjBzIN88US=> MoC3V2FPT0WU
CAL-72 NFnpU|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3iTWM2OD1yLkWzN|g4KM7:TR?= MnjwV2FPT0WU
NH-12 M1HCTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mln0TWM2OD1yLkWzPVU6KM7:TR?= NF\4T|JUSU6JRWK=
SNB75 NVHUXYxPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\sdIlKSzVyPUCuOVU4OyEQvF2= M4P1SnNCVkeHUh?=
BPH-1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW0TotKSzVyPUCuOVY{PDRizszN Mor6V2FPT0WU
NOMO-1 NIXRPWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwNU[zO|Ih|ryP NX\iNlFnW0GQR1XS
G-402 MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7HTWM2OD1yLkW2OFk6KM7:TR?= M3HJeHNCVkeHUh?=
NCI-H2052 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LoVGlEPTB;MD61Olc1OSEQvF2= M320XHNCVkeHUh?=
RCM-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwNUexOlYh|ryP NFK1[WtUSU6JRWK=
COR-L279 NH\w[YxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TLSWlEPTB;MD61O|E5PSEQvF2= NHLTTI5USU6JRWK=
A253 MkjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwNUe1NlUh|ryP M{DIWnNCVkeHUh?=
SK-MM-2 NX7zRWZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwNUe2O|kh|ryP NIX3U|lUSU6JRWK=
NCI-H1703 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rsOGlEPTB;MD61PVQzPyEQvF2= MYjTRW5ITVJ?
UACC-257 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTqb4tzUUN3ME2wMlU6PDh5IN88US=> NYXZcI1XW0GQR1XS
KALS-1 NWnOelh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrTcXZKSzVyPUCuOlAxOTFizszN MXPTRW5ITVJ?
ES5 Ml7KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIqzTWlKSzVyPUCuOlA1QCEQvF2= NWHiOGd3W0GQR1XS
MHH-CALL-2 NXr6emFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwNkC4PFgh|ryP Ml60V2FPT0WU
ChaGo-K-1 MmPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwNkGyNlkh|ryP NYHuSpFvW0GQR1XS
TGBC1TKB Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTBwNkG5PEDPxE1? Mn\PV2FPT0WU
KU-19-19 MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnDcldMUUN3ME2wMlY1PTh4IN88US=> MmDKV2FPT0WU
COLO-684 NXnmeYpkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXGTWM2OD1yLk[1OlEyKM7:TR?= NFWyXJpUSU6JRWK=
LS-1034 NFzkTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fo[mlEPTB;MD62OVgyQSEQvF2= NGX2dG1USU6JRWK=
RT-112 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwNk[1PFch|ryP Mmr1V2FPT0WU
Capan-2 NVHk[YliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\JTWM2OD1yLk[2OlIzKM7:TR?= MXHTRW5ITVJ?
HSC-4 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwNk[2PVgh|ryP NXjROlRbW0GQR1XS
COLO-824 MofyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIi2U|hKSzVyPUCuOlc5OjNizszN MnPpV2FPT0WU
NCI-H2170 Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TRPWlEPTB;MD62PFI2QCEQvF2= MXTTRW5ITVJ?
GDM-1 NEe0XXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFz1SVlKSzVyPUCuOlg1QTRizszN MXPTRW5ITVJ?
KP-4 MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGD2U2xKSzVyPUCuOlk2PzNizszN NX30OIlQW0GQR1XS
VA-ES-BJ MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFj4eZVKSzVyPUCuOlk6QDZizszN MWLTRW5ITVJ?
KM-H2 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHO4[FVKSzVyPUCuO|AxQTFizszN NXK4T4FuW0GQR1XS
HH NXPB[FFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LEXGlEPTB;MD63NFY3OiEQvF2= M3q3e3NCVkeHUh?=
DK-MG MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M364NGlEPTB;MD63NVAyPiEQvF2= NFS4WHNUSU6JRWK=
VM-CUB-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlT0TWM2OD1yLkexNlU6KM7:TR?= NHfIZ5VUSU6JRWK=
COLO-829 MlLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXDTWM2OD1yLkexPVg2KM7:TR?= NVuxW3hCW0GQR1XS
OMC-1 NFLDTYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvPTWM2OD1yLkeyNVA1KM7:TR?= NVXYVHVFW0GQR1XS
NB12 NULZWXIzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTBwN{K1NFQh|ryP M37xSXNCVkeHUh?=
NCI-H28 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzwTWM2OD1yLke0NFg{KM7:TR?= MXnTRW5ITVJ?
A673 Mly4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWj3VWl{UUN3ME2wMlc2OTd5IN88US=> M{LpdnNCVkeHUh?=
LB2241-RCC NWHJSVRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwN{[wPFch|ryP NXToeIlSW0GQR1XS
CCRF-CEM NV3OW4F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTBwN{ewOVIh|ryP MXnTRW5ITVJ?
NCI-H510A M1HHRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofCTWM2OD1yLke3NVg3KM7:TR?= NUXHO4VIW0GQR1XS
SW48 NFn5cVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX36dHZzUUN3ME2wMlc4OzN|IN88US=> M{TKfHNCVkeHUh?=
NCI-H2081 Ml2yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D6bGlEPTB;MD63PFE1PyEQvF2= NUeyXINrW0GQR1XS
RMG-I M{LGc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXtOXhKSzVyPUCuO|gzOTJizszN MnPDV2FPT0WU
LU-99A Mm\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwN{i0NVMh|ryP MmnRV2FPT0WU
KP-N-YS NXWwd3NoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwN{i5NlEh|ryP NIjvcGVUSU6JRWK=
MDA-MB-231 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2X3UGlEPTB;MD64NFE{OSEQvF2= MmHTV2FPT0WU
U031 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWexN|RbUUN3ME2wMlgyPDJ|IN88US=> NELpU4NUSU6JRWK=
EVSA-T MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzSVlNKSzVyPUCuPFE3PzJizszN NVP4XZRYW0GQR1XS
MDA-MB-157 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHyWWJKSzVyPUCuPFIzPzFizszN MoG4V2FPT0WU
EHEB NYDO[WZlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjXWo8zUUN3ME2wMlgzOjd4IN88US=> NHvpRVBUSU6JRWK=
KINGS-1 MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXRTWM2OD1yLkiyOVU2KM7:TR?= MVLTRW5ITVJ?
23132-87 NFvaVXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPDWmJKSzVyPUCuPFI5PDNizszN NVO0eIR6W0GQR1XS
EFO-21 MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwOESwPFkh|ryP NXvxNWRXW0GQR1XS
DOK M4jFb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\LTHhRUUN3ME2wMlg1QCEQvF2= MorYV2FPT0WU
NCI-H2171 MonrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwOES5OkDPxE1? NVLBVmhqW0GQR1XS
NCI-SNU-5 NH\UeZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvXTWM2OD1yLki1OVch|ryP MVzTRW5ITVJ?
SK-N-DZ M2XMdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rObGlEPTB;MD64OVk1OyEQvF2= MmC1V2FPT0WU
SNU-C2B M1;EXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvXR2ZZUUN3ME2wMlg3QDBzIN88US=> NV:5R3VDW0GQR1XS
CP66-MEL MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3YTWM2OD1yLki3NVEh|ryP M{e0NnNCVkeHUh?=
SN12C NXTBfGVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrqWHloUUN3ME2wMlg5PjN5IN88US=> NHq2SZRUSU6JRWK=
A172 M3zxcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3q3ZWlEPTB;MD64PFY6QCEQvF2= MVfTRW5ITVJ?
NCI-H2347 NIDadYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHr1XppKSzVyPUCuPFg4PTNizszN MlHUV2FPT0WU
NCI-H2228 MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\uVGlEPTB;MD64PVM{QSEQvF2= MVnTRW5ITVJ?
SNU-387 NV;JbmlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWj5[YZ6UUN3ME2wMlkxOjZ2IN88US=> M3zxOnNCVkeHUh?=
SK-MEL-24 NWm3eJVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDCcY1KSzVyPUCuPVE{PDRizszN M37IT3NCVkeHUh?=
MDA-MB-468 NEfOSG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHXfmZKSzVyPUCuPVE4OyEQvF2= NIX2OZZUSU6JRWK=
NCI-H1694 NHXoO29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{CwR2lEPTB;MD65NVg4PiEQvF2= M3jnZnNCVkeHUh?=
CCF-STTG1 M4Tzbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnrWTWM2OD1yLkmyOlM4KM7:TR?= MUHTRW5ITVJ?
K052 M2TRXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXznS3VDUUN3ME2wMlk1ODR5IN88US=> MYjTRW5ITVJ?
NCI-H446 M{HCdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX5XY5uUUN3ME2wMlk2ODFizszN MkS3V2FPT0WU
MFE-280 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnERnZKSzVyPUCuPVYzQTFizszN MYPTRW5ITVJ?
KU812 NH7YcYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwOUmzPFkh|ryP NGXyNIdUSU6JRWK=
MDA-MB-361 MnrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Moi5TWM2OD1yLkm5O|c4KM7:TR?= NXLDcmluW0GQR1XS
Raji MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LMPGlEPTB;MT6wNlI3PyEQvF2= NXTKXVJQW0GQR1XS
TE-6 NHfQeHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnNTWM2OD1zLkCzOVY3KM7:TR?= M3XCOXNCVkeHUh?=
CAL-148 M4nKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\JWI96UUN3ME2xMlA1PDR|IN88US=> MUXTRW5ITVJ?
NCI-H1963 M2PG[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonTTWM2OD1zLkC0OVU{KM7:TR?= NVPaN|J{W0GQR1XS
SK-N-AS NW\CTWJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTFwMES2PFUh|ryP NIr3PIFUSU6JRWK=
RERF-LC-MS NXP2VGk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jENmlEPTB;MT6wOlM1QSEQvF2= Mn\lV2FPT0WU
BEN Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvKRpBKSzVyPUGuNFcyOzdizszN MWHTRW5ITVJ?
CAS-1 M3TGTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\FW|hRUUN3ME2xMlA6OTJ|IN88US=> MUTTRW5ITVJ?
SW780 NI\tPHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVPqUlFVUUN3ME2xMlA6OThzIN88US=> NYntPYtyW0GQR1XS
LU-65 Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLM[pNZUUN3ME2xMlA6PDFizszN NXLvOY9tW0GQR1XS
D-283MED Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjtdHdzUUN3ME2xMlEzOjd{IN88US=> MV7TRW5ITVJ?
HCC2157 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvjeGt3UUN3ME2xMlE{PjR{IN88US=> NX:zVpMyW0GQR1XS
RCC10RGB MlrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPzfpBKSzVyPUGuNVQxODZizszN MoP4V2FPT0WU
PLC-PRF-5 MnfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjSW3RvUUN3ME2xMlE2OjJ7IN88US=> MVHTRW5ITVJ?
H4 MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2KxSmlEPTB;MT6xOVQ{QSEQvF2= MVzTRW5ITVJ?
TUR MoDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3TQTWlEPTB;MT6xOVc2OiEQvF2= MX3TRW5ITVJ?
NCI-H2141 M1TkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTFwMUi5OFYh|ryP NWm1XmEzW0GQR1XS
PFSK-1 M3vxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DvWWlEPTB;MT6yNFU{OiEQvF2= M1nue3NCVkeHUh?=
SK-MEL-28 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\iTWM2OD1zLkKzNlIyKM7:TR?= MYLTRW5ITVJ?
SCC-9 NXHHOYMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;ifGlEPTB;MT6yN|Y3PSEQvF2= M3XyfHNCVkeHUh?=
T47D MlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrETWM2OD1zLkKzOlk3KM7:TR?= NVr5d2V4W0GQR1XS
TCCSUP NELocW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfjRWNKSzVyPUGuNlUxOjlizszN M37jO3NCVkeHUh?=
SU-DHL-1 MlrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYm1SItiUUN3ME2xMlI2OTF6IN88US=> NH3MOFBUSU6JRWK=
HL-60 MknJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ThW2lEPTB;MT6yOVU5QCEQvF2= NIHWfo9USU6JRWK=
NCI-H1436 NY\hN5o3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzWVGo2UUN3ME2xMlI3OTR7IN88US=> M3Xvc3NCVkeHUh?=
DMS-114 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS2[WpKSzVyPUGuNlY3OzJizszN NV36T3dYW0GQR1XS
BOKU MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PSXWlEPTB;MT6yPFA6PSEQvF2= NHHC[|JUSU6JRWK=
MS-1 MnfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTFwMkmwOlkh|ryP NF\KVXJUSU6JRWK=
NCI-H661 NYT5TIhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XIfGlEPTB;MT6zNFQ4QCEQvF2= M{\6S3NCVkeHUh?=
HT-3 Mo\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLSVpZKSzVyPUGuN|A2OjlizszN NXzxTWhqW0GQR1XS
CAL-54 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4W5VmlEPTB;MT6zNFczPSEQvF2= MV\TRW5ITVJ?
SW1463 NVnBOWIyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYLJR|UxRTFwM{G4O|Ih|ryP MXzTRW5ITVJ?
COLO-668 NIricZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTFwM{OwOVYh|ryP NE\mNGRUSU6JRWK=
PANC-08-13 Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvhTWM2OD1zLkOzPFA{KM7:TR?= MVvTRW5ITVJ?
BB49-HNC NGPHVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTVN4NqUUN3ME2xMlM1ODFizszN MnXIV2FPT0WU
M059J MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEj5cYtKSzVyPUGuN|U5OzJizszN NGDuR|FUSU6JRWK=
NCCIT MkHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzHTWM2OD1zLkO3PVg5KM7:TR?= NWr5PFlFW0GQR1XS
LN-405 NGCwXpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYL3c25RUUN3ME2xMlM6OjZ2IN88US=> NFHUZ|VUSU6JRWK=
UMC-11 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fGRWlEPTB;MT6zPVk6PiEQvF2= NXrpTXB{W0GQR1XS
NB5 M1nGOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2n4OmlEPTB;MT60NVIzPyEQvF2= NXj0e5MxW0GQR1XS
TE-441-T MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XFTGlEPTB;MT60NlgyPyEQvF2= NGrhXY9USU6JRWK=
ME-180 M1juTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3QTWM2OD1zLkS0N|kzKM7:TR?= MknqV2FPT0WU
HCC70 NIfqfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnj[IZpUUN3ME2xMlQ3ODl4IN88US=> M{m0cnNCVkeHUh?=
no-10 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU\JR|UxRTFwNE[xPFEh|ryP MkLXV2FPT0WU
JEG-3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTFwNUCxN|Ih|ryP MXjTRW5ITVJ?
no-11 MlPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTwbHRLUUN3ME2xMlUxQDh{IN88US=> NFn0S49USU6JRWK=
CHP-126 M1WwTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPpTWM2OD1zLkW2OlkyKM7:TR?= M{nLZXNCVkeHUh?=
EGI-1 NI\6U|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTFwNUiwNlUh|ryP NVXmSmt6W0GQR1XS
D-392MG MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEO5V4dKSzVyPUGuOVk3OyEQvF2= MkXZV2FPT0WU
RT4 NILKWI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTFwNUm2N|ch|ryP M1T6WXNCVkeHUh?=
A204 NVTS[mduT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFwNUm4NFEh|ryP MmezV2FPT0WU
NCI-H1304 MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHDTWM2OD1zLk[zOVkyKM7:TR?= NW\hXpdnW0GQR1XS
Becker NGD3V5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fVV2lEPTB;MT62OFI1OSEQvF2= NWrq[2U2W0GQR1XS
OE19 M{nOdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUj0[os1UUN3ME2xMlY2PTF6IN88US=> NUD5NYlEW0GQR1XS
EKVX NV;p[3RST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnLITWM2OD1zLk[1OlE5KM7:TR?= M4fGbXNCVkeHUh?=
KLE NFvsfVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTZRXJQUUN3ME2xMlY2PzF2IN88US=> NH7KVlhUSU6JRWK=
K-562 NUKxXHczT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\tfZM1UUN3ME2xMlY4ODN5IN88US=> M3ewenNCVkeHUh?=
MDA-MB-175-VII MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3HZRmlEPTB;MT62PFk6PyEQvF2= NG\6b2FUSU6JRWK=
NCI-H716 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vrPGlEPTB;MT62PVMxPCEQvF2= MX;TRW5ITVJ?
Caov-3 NYnFT2UzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXlW3dKSzVyPUGuOlk1OTNizszN MY\TRW5ITVJ?
HCC1187 M4r2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLKTWM2OD1zLkewOVQ2KM7:TR?= NVXNcJFqW0GQR1XS
CAKI-1 Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LV[mlEPTB;MT63NlI6OiEQvF2= M{PzT3NCVkeHUh?=
MOLT-16 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmrZTWM2OD1zLkezN|A4KM7:TR?= M33ZPXNCVkeHUh?=
PC-3 MmnSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTFwN{WwPEDPxE1? MVfTRW5ITVJ?
DV-90 Mn\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTFwN{W1PFUh|ryP M3vpNXNCVkeHUh?=
RXF393 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfpTpFbUUN3ME2xMlc4Ojl2IN88US=> MnT4V2FPT0WU
SK-NEP-1 M1zYVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlm3TWM2OD1zLkiyN|M6KM7:TR?= MmLKV2FPT0WU
HCC1419 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIP5VVlKSzVyPUGuPFI3QTJizszN MnLIV2FPT0WU
BV-173 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TLNGlEPTB;MT64Nlk6PSEQvF2= M37EfXNCVkeHUh?=
MKN7 M{\0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfYV2pFUUN3ME2xMlg6OjJizszN MofZV2FPT0WU
LAN-6 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fK[GlEPTB;MT64PVU2OyEQvF2= M4jYRXNCVkeHUh?=
Mo-T MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[wVXJKSzVyPUGuPVAxOzlizszN NWG5codCW0GQR1XS
HCC1395 M1LDcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHmRnhKSzVyPUGuPVI5PjNizszN M{nJWXNCVkeHUh?=
HC-1 NF7xV3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFGx[WxKSzVyPUGuPVM1PyEQvF2= Mmq4V2FPT0WU
HPAF-II NFXET3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jjWWlEPTB;MT65OFQyQCEQvF2= NYfVWlF{W0GQR1XS
CPC-N MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[wTWM2OD1zLkm4NFAzKM7:TR?= MnnzV2FPT0WU
MKN45 NYTSfHVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHoTWM2OD1zLkm5NVE6KM7:TR?= M3WzUnNCVkeHUh?=
NCI-H1693 NUfuXIZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S1dGlEPTB;Mj6wNFQ{OyEQvF2= MXvTRW5ITVJ?
SHP-77 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnlVWZKSzVyPUKuNFA2OzNizszN MVrTRW5ITVJ?
NCI-H1522 M4jFfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXIV29KSzVyPUKuNFE4OjRizszN MXTTRW5ITVJ?
SW1573 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXrTWM2OD1{LkCyNkDPxE1? NGTjSXlUSU6JRWK=
DBTRG-05MG MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;MVGlEPTB;Mj6wOlA5PyEQvF2= M1PBNnNCVkeHUh?=
SCC-4 NXzZ[oJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrENVlKSzVyPUKuNVQ{OSEQvF2= MV\TRW5ITVJ?
DMS-153 MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Hhe2lEPTB;Mj6xOlY3QCEQvF2= M3XqT3NCVkeHUh?=
MDA-MB-415 NU[3cWhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTJwMUe1NkDPxE1? NGDtW2hUSU6JRWK=
NCI-H2126 NYD3T4dsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXjSFlKSzVyPUKuNlI5QDhizszN MUjTRW5ITVJ?
MDA-MB-453 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXvW[4tuUUN3ME2yMlI{OzJizszN NEf0eFJUSU6JRWK=
U-87-MG MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnGSIlrUUN3ME2yMlI5PTl{IN88US=> NVHGcXozW0GQR1XS
LNCaP-Clone-FGC NIDNPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJwM{CxNFIh|ryP M2npdXNCVkeHUh?=
NCI-H1581 NWPVVIQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTJwM{KxNFUh|ryP MoLpV2FPT0WU
BC-3 Mn22S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUnNSJo5UUN3ME2yMlM3PTB7IN88US=> M3X5NXNCVkeHUh?=
HCC38 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTJwM{i0OFch|ryP MoTKV2FPT0WU
HCC2218 NYniZY9tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3IepJpUUN3ME2yMlQxQDB7IN88US=> NYLmTYZ[W0GQR1XS
RO82-W-1 MoDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJwNEGyOUDPxE1? MYLTRW5ITVJ?
C2BBe1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYf2b3BoUUN3ME2yMlQyPTd6IN88US=> MXHTRW5ITVJ?
LAMA-84 NIHzfoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1ezdGlEPTB;Mj61O|M3QCEQvF2= NEL1VJZUSU6JRWK=
GMS-10 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHVTWM2OD1{LkW3OlEyKM7:TR?= NXexXlNLW0GQR1XS
GCT MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYeydpVXUUN3ME2yMlU5Pjl2IN88US=> MXHTRW5ITVJ?
SK-CO-1 M{[3eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTRdYNLUUN3ME2yMlYyPjZizszN MX;TRW5ITVJ?
NCI-H526 NVr6UXFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHa[HNKSzVyPUKuOlM1PSEQvF2= NWL5PGptW0GQR1XS
SW1088 NF\5e29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojmTWM2OD1{Lke3PFM6KM7:TR?= MmfLV2FPT0WU
HT55 NGn0ZphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37zN2lEPTB;Mj63PFY6PSEQvF2= M1XETXNCVkeHUh?=
NB10 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PVdmlEPTB;Mj64NVc1QCEQvF2= NVPJVHViW0GQR1XS
UACC-893 M2CyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnW0TWM2OD1{Lki1O|Q6KM7:TR?= MXPTRW5ITVJ?
NCI-H1618 NGfMS2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTJwOEixOVMh|ryP MkfnV2FPT0WU
NCI-H1092 NXzYUVFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIr1WpVKSzVyPUOuNFc5OTJizszN MXTTRW5ITVJ?
SBC-1 M{n6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1qzUGlEPTB;Mz6wPFU2OyEQvF2= Ml7YV2FPT0WU
NCI-H1623 NGTzO4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLmUXZKSzVyPUOuNFk{PCEQvF2= M2i2OXNCVkeHUh?=
SiHa M1TzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTNwMUG5O|ch|ryP NHHMOnpUSU6JRWK=
D-263MG MnezS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4ryS2lEPTB;Mz6xOFc5QCEQvF2= NX;IRVdmW0GQR1XS
NCI-H1573 NUPFPYs6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTNwMUm2OFEh|ryP MoPHV2FPT0WU
NCI-H82 M4nJd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTNwM{S0N|kh|ryP MY\TRW5ITVJ?
NCI-H2196 NWTVbGhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3HJSWlEPTB;Mz6zOVAxQCEQvF2= NYXLW4c3W0GQR1XS
MFM-223 NYHjXWM4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DNeWlEPTB;Mz6zO|M2OSEQvF2= NGPKeoJUSU6JRWK=
COLO-678 NVLmTnVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TiZWlEPTB;Mz6zPFE5PiEQvF2= M2Tlc3NCVkeHUh?=
EW-3 NVLVPXdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\DUpBDUUN3ME2zMlQxQTVizszN M1PmfXNCVkeHUh?=
MHH-NB-11 NVrpNZlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1uzd2lEPTB;Mz60OFA3QSEQvF2= MXLTRW5ITVJ?
EM-2 NWTkcHplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfoVIxiUUN3ME2zMlY{QThizszN MVHTRW5ITVJ?
FTC-133 MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\F[nZKSzVyPUOuOlU1PThizszN M4LQcnNCVkeHUh?=
NCI-H209 M2TsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV23epBSUUN3ME2zMlY4PjV|IN88US=> MoTjV2FPT0WU
TGBC24TKB NGjYRZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLUXW5EUUN3ME2zMlY5OzV3IN88US=> MmPyV2FPT0WU
LC-1F MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIK1eYVKSzVyPUOuO|E4PjRizszN NEHHPWVUSU6JRWK=
C-4-II MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojrTWM2OD1|Lke1OlQ{KM7:TR?= M1nkUnNCVkeHUh?=
NCI-H1650 M{j1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHKdY9KSzVyPUOuO|g1PTVizszN NXH5enJ{W0GQR1XS
JVM-2 M4jJO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TG[GlEPTB;Mz65N|Y{QSEQvF2= MnS4V2FPT0WU
CaR-1 M4DUWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvNTWM2OD1|Lkm3OlE4KM7:TR?= MoKxV2FPT0WU
MDA-MB-134-VI M2W1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHEUYs1UUN3ME20MlAzQTV{IN88US=> MWrTRW5ITVJ?
NCI-H719 NH3WRopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rE[2lEPTB;ND6xOVM5QCEQvF2= MW\TRW5ITVJ?
GOTO NWm3O2ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofGTWM2OD12LkK5O|A2KM7:TR?= Ml7yV2FPT0WU
NCI-N87 MknwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LnVGlEPTB;ND6zPFgzOSEQvF2= M2GzUnNCVkeHUh?=
NB6 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7hXXpKSzVyPUSuOFI2ODlizszN NHrhV4FUSU6JRWK=
DSH1 NUTyVWRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTRwNEexNVYh|ryP NX\BOGRSW0GQR1XS
BT-20 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTRwNEmwNFIh|ryP NH\GUFBUSU6JRWK=
NCI-H1882 MoXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHSydm5KSzVyPUSuOVA2PyEQvF2= NHnEXoxUSU6JRWK=
WM-115 Mo\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfRS2JJUUN3ME20MlUxQDhzIN88US=> MWLTRW5ITVJ?
SKG-IIIa M2G4S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXPfmhWUUN3ME20MlY4PzdizszN MWHTRW5ITVJ?
NCI-H69 MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYO3XWVoUUN3ME20MlcxOjd3IN88US=> M4fmOHNCVkeHUh?=
MSTO-211H MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3POOmlEPTB;ND64N|U3PSEQvF2= MUnTRW5ITVJ?
Mewo NXjocGVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTRwOU[zNVMh|ryP M{HWe3NCVkeHUh?=
GI-ME-N MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWf0TWQyUUN3ME21MlAxPTB7IN88US=> MliyV2FPT0WU
T98G M2XyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTZTVBKSzVyPUWuNFY2ODhizszN NUHKTJltW0GQR1XS
ECC4 NI[yTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjUS3FKSzVyPUWuNFk{PzJizszN NF65TVNUSU6JRWK=
EW-11 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTVwMUiwPVkh|ryP NXXsZllEW0GQR1XS
COLO-800 NWfzbG86T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTVwMUmzOFkh|ryP NV3BflJSW0GQR1XS
NCI-H1755 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTOTWM2OD13LkKzNFI4KM7:TR?= NYjSb5FzW0GQR1XS
KMS-12-PE MomxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHiTWM2OD13LkO1NFg2KM7:TR?= MUDTRW5ITVJ?
HCC1954 NUXJUVlFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPGPXlPUUN3ME21Mlg2QTdzIN88US=> MXjTRW5ITVJ?
NCI-H187 NXHO[4RlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;tPZlIUUN3ME21MlkzQTh7IN88US=> MXHTRW5ITVJ?
LU-165 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTVwOUmwNFIh|ryP M{jzbXNCVkeHUh?=
YAPC M1ztVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPyZohSUUN3ME21Mlk6ODZ6IN88US=> NXG3[XF4W0GQR1XS
LU-139 NFTFc3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37WV2lEPTB;Nj6wPFM3QCEQvF2= MVnTRW5ITVJ?
D-502MG NGfnVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkm0TWM2OD14LkOyNFQ4KM7:TR?= M1XNVXNCVkeHUh?=
IST-SL1 NWXpPI81T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXSN|Z3UUN3ME22MlU{QTR6IN88US=> NY\uPYJsW0GQR1XS
DG-75 NWXnO|JKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFyyWopKSzVyPU[uPFg4QDZizszN M1znXnNCVkeHUh?=
NCI-H1155 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXKbG5KSzVyPU[uPVU2QDFizszN Mnm5V2FPT0WU
EFE-184 NITyfZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;IRmlEPTB;Nz6zNVY6PSEQvF2= NH61V3hUSU6JRWK=
AsPC-1 MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVn6TlUyUUN3ME23MlQ5QDB5IN88US=> MmH2V2FPT0WU
SW948 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHUTWM2OD15LkW4N|k2KM7:TR?= MlzWV2FPT0WU
NCI-H524 M1rpXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjaTWM2OD17LkW4OlI5KM7:TR?= MWfTRW5ITVJ?
KOSC-2 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjOdohKSzVyPUmuOlI5OzRizszN M{nsbXNCVkeHUh?=
T-24 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnuNmxKSzVyPUmuPVQ1OTVizszN NIfTWXBUSU6JRWK=
NCI-H748 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFyLk[zPVch|ryP MmO0V2FPT0WU
NCI-H23 M3fnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfjTWM2OD1zMD62OFQzKM7:TR?= M1nvbHNCVkeHUh?=
UACC-812 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\3TWM2OD1zMT63NVch|ryP M1fIXXNCVkeHUh?=
SCLC-21H NILVcoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrRcopKSzVyPUGyMlE2PTFizszN M2njb3NCVkeHUh?=
NCI-SNU-16 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrtTWM2OD1zMz6xNlU5KM7:TR?= NUHPfXVHW0GQR1XS
HD-MY-Z MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3e3VGlEPTB;MUSuOlM3OyEQvF2= NH;JNWtUSU6JRWK=
SK-N-FI NHLwTm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYXjNZk6UUN3ME2xOE45QTF{IN88US=> NF7BRWxUSU6JRWK=
LB647-SCLC NXfOZodQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTF3LkexPVUh|ryP MUTTRW5ITVJ?
NCI-H345 NIrCTVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnuXIlKSzVyPUG3MlM1OyEQvF2= MV;TRW5ITVJ?
NCI-H1563 NX7MXWNRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zjbWlEPTB;MUiuO|YxOSEQvF2= NWD2Ro5wW0GQR1XS
RL MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIr0OZNKSzVyPUKxMlI3PTZizszN NHL4bnFUSU6JRWK=
KY821 MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvEc5ZKSzVyPUKyMlA2PTNizszN NYHJTWRwW0GQR1XS
JVM-3 NEjBbWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTnTWM2OD1{NT6wOFE{KM7:TR?= M4HsV3NCVkeHUh?=
NCI-H1793 M4T3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIP3TXdKSzVyPUK4MlU1QTlizszN NWTCRmNVW0GQR1XS
LU-134-A NEK5OolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TmfGlEPTB;M{CuNlA{PyEQvF2= NX;xSWlsW0GQR1XS
NCI-H1395 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fESGlEPTB;M{KuNlQ{OSEQvF2= NWO2VY13W0GQR1XS
NCI-H1993 NIXtSZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HtNWlEPTB;M{KuPFIyQCEQvF2= MoHqV2FPT0WU
P31-FUJ MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTN|LkS4PVkh|ryP Mkm4V2FPT0WU
LS-513 NUPqWIJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7me4RKSzVyPUO1Mlg5PzlizszN NYj1O|ZNW0GQR1XS
SK-MEL-1 MlXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWi2NlZ{UUN3ME20NE4{PDl7IN88US=> NEXJbGNUSU6JRWK=
SW684 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jsVmlEPTB;NEOuPVY3OSEQvF2= NXLZXlRlW0GQR1XS
COR-L88 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\wTWM2OD12ND6wOlY2KM7:TR?= NEXPUlhUSU6JRWK=
NCI-H889 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGm4UYpKSzVyPUS1MlAxQDdizszN MorpV2FPT0WU
TALL-1 NVHXR5FUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P5[mlEPTB;NE[uNVE6QSEQvF2= NXztN3JtW0GQR1XS
KARPAS-299 MnTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LKUWlEPTB;NEeuNVk6OyEQvF2= NVLSNJNmW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. [1]

Protocol

Kinase Assay:[1]
+ Expand

Bcl-2 Binding affinity calculation:

A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. [4] As a control in determining the reliability of the calculation, predicted binding affinities Ki) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.
Cell Research:[2]
+ Expand
  • Cell lines: Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs)
  • Concentrations: ~10 μM
  • Incubation Time: 48-72 hours
  • Method: Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 104 per well for HMCLs or 5~10 × 103 for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used.
  • Formulation: Obatoclax (tartrate salt) is formulated in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated at a concentration of 0.6 mg/mL in 9.48% polyethylene glycol, 0.38% polysorbate 20, 1.2 m
  • Dosages: 0.0313, 0.25, 0.5 and 2 mg/kg
  • Administration: Administered intravenously (tail vein) once a day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 83 mg/mL (200.73 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 413.49
Formula

C20H19N3O.CH4O3S

CAS No. 803712-79-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01563601 Withdrawn Extensive-stage Small Cell Lung Cancer Cephalon|Teva Pharmaceutical Industries August 2012 Phase 3
NCT01238146 Withdrawn Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Splenic Marginal Zone Lymphoma National Cancer Institute (NCI) October 2010 Phase 1|Phase 2
NCT00918931 Terminated Leukemia|Systemic Mastocytosis M.D. Anderson Cancer Center|Gemin X June 2009 Phase 2
NCT00933985 Terminated Acute Leukemias of Ambiguous Lineage|Acute Undifferentiated Leukemia|Angioimmunoblastic T-cell Lymphoma|Blastic Phase Chronic Myelogenous Leukemia|Childhood Burkitt Lymphoma|Childhood Chronic Myelogenous Leukemia|Childhood Diffuse Large Cell Lymphoma|Childhood Immunoblastic Large Cell Lymphoma|Childhood Nasal Type Extranodal NK/T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Noncutaneous Extranodal Lymphoma|Peripheral T-cell Lymphoma|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Childhood Anaplastic Large Cell Lymphoma|Recurrent Childhood Grade III Lymphomatoid Granulomatosis|Recurrent Childhood Large Cell Lymphoma|Recurrent Childhood Lymphoblastic Lymphoma|Recurrent Childhood Small Noncleaved Cell Lymphoma|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent/Refractory Childhood Hodgkin Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|Relapsing Chronic Myelogenous Leukemia|Small Intestine Lymphoma|Unspecified Childhood Solid Tumor Protocol Specific National Cancer Institute (NCI) June 2009 Phase 1
NCT00719901 Terminated Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma National Cancer Institute (NCI) July 2008 Phase 1|Phase 2
NCT00724841 Terminated Metastatic Melanoma Gemin X|Teva Pharmaceutical Industries June 2008 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) supplier | purchase Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) cost | Obatoclax Mesylate (GX15-070) manufacturer | order Obatoclax Mesylate (GX15-070) | Obatoclax Mesylate (GX15-070) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID